Navigation Links
Castle Biosciences Launches Tissue Repository for Eye Cancer Patients
Date:9/30/2013

FRIENDSWOOD, Texas, Sept. 30, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced today the availability of a tumor tissue repository for patients whose tumors are being tested with the Company's gene test for uveal, or ocular, melanoma. Patients will now have the option of storing an additional sample of their tumor free of charge for up to five years, and will be able to access it to take advantage of future developments in the disease.

Castle Biosciences would provide the samples to third parties only with permission of the patient for legitimate research, treatment guidance or diagnostic purposes. Castle will not use the tumor samples for its own research purposes, but rather retain the sample for future patient request.

"Retaining tumor samples could prove extremely important for uveal melanoma patients given the rapid pace of advances in the field," said Dr. J. William Harbour, Professor of Ophthalmology, Vice Chairman for Translational Research and Director of the Ocular Oncology Service at the Bascom Palmer Eye Institute in Miami. "Patients may find that their tumor's genetic information can guide emerging treatments, entry into clinical studies or further prognostic testing."

The DecisionDx-UM test helps predict a patient's risk of their eye cancer spreading to other organs, predominantly the liver. The test requires a small sample of the patient's tumor, with an additional sample obtained simultaneously should the patient wish to store it in the tissue repository. The Castle repository will be the only broadly available program of its kind.

Commented Grant Allen, Chairman of the Ocular Melanoma Foundation, "This is an important first step in empowering patients as they navigate the diagnosis stage and their own unique disease characteristics. Patients choosing to store a tumor sample could benefit from future trea
'/>"/>

SOURCE Castle Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Animal Rehabilitation and Wellness Center Gives Castle Rock Golden Retriever a Second Chance to Enjoy Life with Stem Cell Therapy
2. Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
3. Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting
4. MD Biosciences Publishes the Characterization of a Porcine Model of Post-operative Or Incisional Pain in the European Journal of Pain
5. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
6. SAGE Labs, Inc. Licenses CRISPR/Cas9 genome engineering technology from Caribou Biosciences, Inc.
7. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
8. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
9. Sangamo BioSciences Proposes Public Offering Of Common Stock
10. Rancho BioSciences Partners with OmicSoft for Manual Data Curation
11. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  UBM Medica US announces ... leading online community to help oncologists and other ... information available regarding the use of targeted therapies ... March is National Kidney Cancer ... effective adjuvant treatment options for renal cell carcinoma ...
(Date:3/5/2015)... e2b teknologies , a premier ... Northeast Ohio, today announced a leading independent multi-specialty physician ... upgrade to the latest version of Sage 100 ... of its kind in the region, the organization has ... so efficiency and data accessibility are paramount to their ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
(Date:3/4/2015)... N.Y. , March 4, 2015  Brooklyn residents ... their acute and chronic pain and injuries. Nunzio ... announce the grand opening of his NJS Physical Medicine ... on Thursday, March 5, 2015. Health Plus ... facility, which is located at 1178 Flatbush Avenue. This ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... June 10 BioSpecifics,Technologies Corp. (OTC BB BSTC.OB-News) ... unregistered shares of its common stock priced at ... $1,500,000. The shares,were purchased by certain private investors ... a company managed PIPE transaction at a premium ...
... June 10 DURECT Corporation,(Nasdaq: DRRX ) ... for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to the ... drug, is a long,acting oral formulation of oxycodone ... DURECT,s ORADUR technology, Remoxy is designed to resist,common ...
... pipeline of biologics ... disease and cancer, CAMBRIDGE, Mass., June 10 Merrimack ... of,novel treatments for autoimmune disease and cancer, today announced that ... financing., Existing and new investors participated in the financing ...
Cached Biology Technology:New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2
(Date:2/5/2015)... , 5. Februar 2015 ... spezialisiertes Logistikunternehmen und hat eine neue Marketingkampagne ... Logistikfirma (Clinical Logistics Organization – CLO) der ... Kampagne lautet First , mit Schwerpunkt ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 Logo ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... 27, 2007 New protocol and software developments are helping ... making it easier for growers to use previously ineffectual ... Historically, gaps between researchers and producers, as well ... decisions, have all contributed to data languishing on hard ...
... new and extraordinary $22 million gift to the University of ... institute one with a mission of supporting fundamental research ... of a broad range of human diseases. The A. ... Medical School, is named for the retail pioneer whose funding ...
... ANGELES (September 25, 2007) Stem cell therapy for ... the media will be the focus of the keynote ... the Treatment of Cardiovascular Disease conference. Conducted by Cedars-Sinai ... 4 and 5, the conference is co-sponsored by the ...
Cached Biology News:Emphasizing the 'precision' in precision agriculture 2$22 million gift from Alfred Taubman launches new biomedical research institute 2$22 million gift from Alfred Taubman launches new biomedical research institute 3$22 million gift from Alfred Taubman launches new biomedical research institute 4Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 2Cardiologists and heart surgeons meet for 'Controversies and Advances' conference 3
RNase-Free DNase 50 l...
DNA polymerase I, large fragment...
... Exonuclease III digests duplex DNA in ... end, 5'-overhang or nick, producing stretches of ... degradation by Exonuclease III proceeds at a ... Because the rate of exonucleolytic excision of ...
... from yeast/leuconostoc overproducer ATP: D-hexose ... 2.7.1.1/1.1.1.49. One unit of HK ... D-glucose in 1 min at ... unit of G6P-DH will oxidize ...
Biology Products: